Azzet reports on three stocks with price moving updates today.
Predictive Discovery soars on takeover offer from Perseus ~
Shares in Predictive Discovery (ASX: PDI) were up 17.1% by 1:40 pm AEDT (2:40 am GMT) to $0.73 after the gold miner told the market that its largest shareholder (17.8%) and rival gold miner Perseus Mining (ASX: PRU) has made an unsolicited bid to take the company out.
The miner’s board wasted no time in telling the market that it considered the scrip offer to be superior to its $2.5 billion merger plan with Canadian suitor Robex Resources (ASX: RXR).
However, Robex now has a five-business-day matching period to table a new proposal.
Meanwhile, both Perseus and Robex (CDIs) fell on the strength of today’s announcement, down 3% and 21.5% respectively.
Perseus wants to acquire all shares not already owned by it in exchange for 0.136 new Perseus shares per Predictive Discovery share.
Based on the Perseus share price at yesterday's close, this values each Predictive Discovery share at 77.8 cents.
This implies a fully diluted valuation of approximately $2.1 billion and represents a premium of 24.5% to its last close price on 2 December.
The takeover offer is understood to include a valuable $37 million unsecured loan facility from Perseus to help – with the aid of Perseus’s experienced projects team - optimise the development of Predictive's flagship Bankan Gold Project in northeast Guinea.
The loan facility will also be used to pay any termination fee payable under the Robex arrangement agreement.
By incorporating Bankan's resources, Perseus plans to advance its goal of becoming West Africa's next mid-tier gold producer by significantly ramping up its production scale and diversifying its operations across a fifth African jurisdiction.
Perseus also plans to enhance its overall portfolio value by tapping into Bankan’s untouched exploration potential.
Commenting on today’s announcement, Perseus told the market that the ASX 300 gold stock would be an excellent strategic fit and enhance its portfolio quality and African gold platform.
“… as one of the largest undeveloped gold projects in Africa, Bankan adds material ounces and mine life across a fifth jurisdiction, with its production of ~249koz adding to Perseus's existing production of 500-600koz per annum,” the company said.
“Perseus is uniquely placed to de-risk, optimise and ultimately unlock the full potential of Predictive's Bankan Gold Project (Bankan) in Guinea, with its world class projects team currently executing a similar development at Nyanzaga; Enhanced growth profile: consistent with Perseus's M&A track record, this transaction is financially compelling and is expected to materially enhance earnings, cash flow and production going forward.”
Whether Robex decides to make a counteroffer remains to be seen; the merger agreement it entered into with Predictive early October, followed by the latter losing some exploration licences and experiencing delays to its final exploitation permit.
The deal would have seen Predictive Discovery acquire all outstanding Robex Resources shares - forming a $2.35 billion ASX-listed entity – with Robex shareholders receiving 8.667 Predictive Discovery Shares for each Robex Resources share.
Predictive Discovery has a market cap of $1.9 billion; the share price is up 208% in one year and up 23% in the last week.
The stock appears to be in a long-term uptrend, confirmed by multiple indicators.
Consensus is Strong Buy.
Sunrise Energy Metals continues bull run after latest fund raise
Shares in Sunrise Energy Metals (ASX: SRL) were up around 2.8% after the miner told the market this morning it has secured $18.865 million through a follow-on placement of 3.85 million shares at $4.90 each, a 15.3% premium to its previous placement in November.
Together with the $46 million raised in the last month, the additional fundraising announced today is expected to ramp up pre-construction work at the Syerston Scandium Project in NSW, a globally significant scandium, nickel, and cobalt resource.
The company aims to supply critical materials for the growing electric vehicle and renewable energy sectors.
The newly acquired funds, in conjunction with the $46 million raised over the past month, will be used to expedite pre-construction activities at the Syerston Scandium Project.
Pre-construction activities are expected to include detailed engineering work, establishing crucial water and power connections, conducting infill drilling programs, and initiating early equipment contracting processes.
Commenting on today’s update, managing director Sam Riggall told the market that combined funding, plus potential option proceeds and conditional support from the U.S. EXIM Bank for up to US$67 million ($102 million), ensures the project is adequately financed.
The company said the capital will help de-risk critical construction-path activities ahead of a final investment decision.
Shares in Sunrise have been on a tear since trading at $1.65 in early September.
Market expectations of the company becoming the West's major primary scandium producer have seen the stock’s share price surge more than 2,500% over the past twelve months.
While a Lockheed Martin offtake deal, U.S. government financing interest, and a freshly completed $46 million capital raise suggest the company is transitioning from explorer to developer, it remains to be seen if the market still sees upside at current levels.
In October, the U.S. defence giant secured an option to purchase up to 25% of Syerston’s annual scandium output over five years.
As well as positioning Sunrise as a potential long-term supplier for aerospace and defence applications, it also offers significant validation of the project’s commercial viability.
The Syerston project is understood to hold the world’s largest and highest-grade primary scandium deposit.
An updated resource estimate released in September showed 45.9 million tonnes grading 414 parts per million scandium, containing over 19,000 tonnes of the metal, a 98 per cent increase from previous estimates.
To put the Syerston project into context: global scandium production sits below 40 tonnes annually, with China controlling most supply.
Assuming Syerston delivers its projected 60 tonnes per year over a 32-year mine life, it stands to materially reshape global supply dynamics.
Sunrise Energy Metals has a market cap of $957 million; the share price is up 2,912% in one year and up 60% in the last week.
The stock appears to be in a strong bullish trend, confirmed by multiple indicators.
Consensus is Strong Buy.
4D Medical rallies after expanding distribution agreement with Philips
Shares in 4D Medical (ASX: 4DX) were trading 12.4% higher following revelations that the mid-cap healthcare stock has expanded its distribution agreement with Philips, securing a minimum US$10 million ($15 million) in CT:VQ orders over two years.
The partnership with Koninklijke Philips NV (NYSE: PHG) will leverage its extensive commercial network for its FDA-cleared, non-contrast computed tomography (CT) ventilation and perfusion imaging solution, CT:VQ.
With an addressable market exceeding US$2.6 billion globally and significant clinical benefits, 4D Medical told the market today it is poised to capture a substantial market share, anticipating long-term growth in the demand for its advanced ventilation-perfusion scanning technology.
The expanded agreement will see Philips add CT:VQ to its North American product portfolio, distributing the technology through its established commercial infrastructure and customer relationships.
Philips is understood to have agreed to a minimum of approximately $15 million (US$10 million) in customer orders in 2026 and 2027.
Commenting on today’s update, management told the market that Philips will allocate dedicated sales and clinical specialists carrying CT:VQ sales targets.
Joint marketing initiatives and co-branding campaigns are also being initiated to drive market awareness and adoption, with RSNA (Radiological Society of North America) 2025 marking the first major international launch event for the collaboration.
To the uninitiated, CT:VQ is being described as the world's first technology capable of extracting quantitative ventilation-perfusion (VQ) data from routine non-contrast CT scans.
The technology measures regional lung tissue motion and local density changes to generate comprehensive ventilation and perfusion maps without requiring radiotracers or contrast agents.
It notes that the solution addresses several critical limitations of traditional nuclear VQ imaging.
By eliminating radiotracers, the technology streamlines scheduling, improves patient access, and removes complex handling requirements and regulatory constraints. Importantly, CT:VQ integrates seamlessly with existing CT protocols.
There are over one million nuclear VQ scans performed annually in the United States, with an average reimbursement rate of approximately US$1,150 per scan.
Management points out that this represents an addressable market of more than US$1.1 billion annually in the U.S., estimated at over US$2.6 billion globally.
Management expects the introduction of the solution into the market to drive long-term growth in demand for ventilation-perfusion scans beyond the traditional nuclear VQ indications.
Early November, Bell Potter doubled its target price on 4D Medical to $2.25 and flagged a 41% potential increase from its current price, thanks to optimistic growth prospects.
“The September 2025 approval of 4DX's CT:VQ product by the FDA has become a major catalyst for a resurgence of interest in the 4DX tech,” the broker noted.
“Commercialisation will be an ongoing process, much like the experience of ASX listed peers, including TLX, NAN, PME and PNV, each of which started from humble beginnings in the U.S., followed by a period of rapid expansion.”
4D Medical has a market cap of $975 million; the share price is up 293% in one year and up 19% in the last week.
The stock appears to be in a long-term uptrend, confirmed by multiple indicators.
Consensus is Strong Buy.
This article does not constitute financial or product advice. You should consider independent advice before making financial decisions.
